In the TCGA cohort, glioma patients with the clinicopathological characteristics of age >50 years, more malignant type of 2016 WHO classification, higher grade, IDH wild type, and MGMT promoter unmethylated showed significantly higher levels of risk score, while no risk score differences were observed between patients satisfied by gender and 1p19q codeletion (Figures 3B–H). This evidence concerns the gene MGMT and central nervous system cancer.